Biotech - Spark Newswire

2 minute read

Dicerna Initiates Patient Dosing In ESTRELLA Phase 2 Clinical Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Today, 11:46 AM

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced it has initiated

DRNA

1 minute read

Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity

By Vandana Singh

Today, 11:46 AM

The FDA has accepted for review Fennec Pharmaceuticals Inc’s (NASDAQ:FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to…

FENC

1 minute read

Biolase Granted Patent Titled ‘Display screen including a dental laser graphical user interface’

By Bill Haddad

Today, 11:46 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5512&f=G&l=50&d=PTXT&p=111&S1=20210622&OS=20210622&RS=20210622

BIOL

1 minute read

Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters

By Vandana Singh

Today, 11:46 AM

In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against…

ABBV

3 minute read

Innate Pharma Highlights Presentation Of Preliminary Data from TELLOMAK Trial

By Bill Haddad

Today, 11:46 AM

First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for

IPHA

1 minute read

Roche’s Alzheimer’s Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows

By Vandana Singh

Today, 11:46 AM

Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE:LLY) and Roche Holding AG’s (OTC:RHHBY) failed to improve symptoms of Alzheimer’s disease (AD)…

LLY

3 minute read

Lineage Cell Therapeutics To Submit Amendment To IND For OPC1 To Support A Phase 1 Trial To Evaluate Safety And Performance Of Neurgain Technologies Inc.’s Parenchymal Spinal Delivery System

By Bill Haddad

Today, 11:46 AM

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on the clinical advancement of

LCTX

1 minute read

Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford

By Vandana Singh

Today, 11:46 AM

Inhibrx Inc (NASDAQ:INBX) has initiated a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma, a type of bone cancer…

INBX

3 minute read

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival In Patients With Persistent, Recurrent Or Metastatic Cervical Cancer

By Bill Haddad

Today, 11:46 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based

MRK